Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists. Ellis P, et al. Lancet. 2009 May 16;373(9676):1681-92. doi: 10.1016/S0140-6736(09)60740-6. Lancet. 2009. PMID: 19447249 Free PMC article. Clinical Trial.
Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).
Hall E, Cameron D, Waters R, Barrett-Lee P, Ellis P, Russell S, Bliss JM, Hopwood P; TACT Trial Investigators. Hall E, et al. Eur J Cancer. 2014 Sep;50(14):2375-89. doi: 10.1016/j.ejca.2014.06.007. Epub 2014 Jul 24. Eur J Cancer. 2014. PMID: 25065293 Free PMC article. Clinical Trial.
Pertuzumab for the treatment of metastatic breast cancer.
Langdon SP, Cameron DA. Langdon SP, et al. Among authors: cameron da. Expert Rev Anticancer Ther. 2013 Aug;13(8):907-18. doi: 10.1586/14737140.2013.814419. Expert Rev Anticancer Ther. 2013. PMID: 23984893 Review.
Lapatinib for inflammatory breast cancer.
Hall PS, Hanby A, Cameron DA. Hall PS, et al. Among authors: cameron da. Lancet Oncol. 2009 Jun;10(6):538-9. doi: 10.1016/S1470-2045(09)70120-2. Lancet Oncol. 2009. PMID: 19482243 No abstract available.
The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses.
Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher MJ. Campbell HE, et al. Eur J Cancer. 2011 Nov;47(17):2517-30. doi: 10.1016/j.ejca.2011.06.019. Epub 2011 Jul 7. Eur J Cancer. 2011. PMID: 21741831
Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long-term follow-up.
Kunkler IH, Kerr GR, Thomas JS, Jack WJ, Bartlett JM, Pedersen HC, Cameron DA, Dixon JM, Chetty U; Edinburgh Breast Group. Kunkler IH, et al. Among authors: cameron da. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):829-38. doi: 10.1016/j.ijrobp.2011.08.018. Epub 2011 Dec 22. Int J Radiat Oncol Biol Phys. 2012. PMID: 22197227
301 results